Mining
BlinkLab, a company founded by neuroscientists at Princeton University over the past several years, has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old.
This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors, with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge the most advanced technological innovations with groundbreaking scientific research.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX health stocks developing tech to bridge labour gaps
Health & Biotech
ASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trial
Health & Biotech
Lodge Partners sees 430% upside for Blinklab, developer of smartphone autism test
Health & Biotech
Health Check: Farewell, adieu as Argent Biopharma holders back ASX delisting
Health & Biotech
Bio Curious: Phone autism test strives to make diagnosis quicker and more blinkin’ simple
Health & Biotech
BlinkLab partners with INTER-PSY to run clinical trial for its early autism diagnosis platform
Health & Biotech
Digital prescription: ASX stocks transforming healthcare sector
Health & Biotech
BlinkLab smartphone platform could transform autism and ADHD diagnosis
Health & Biotech
Blinklab teams up with Monash Uni to monitor effects of ketamine
Health & Biotech
ASX Quarterly Health Wrap – Who kicked off a pivotal trial last quarter?
Health & Biotech
BlinkLab partners with Mental Care Group to advance ADHD diagnostics in Europe
Health & Biotech
ASX Health Stocks: HITIQ secures US patent; BlinkLab joins forces in Europe to transform ADHD diagnosis
Health & Biotech
National biotech summit shows off a wealth of healthcare and medical innovation
Health & Biotech
Can BlinkLab’s autism diagnosis tool replicate the huge success of ResApp?
IPO Watch
IPO Wrap: Life360 becomes latest ASX company to seek New York listing; and 2 upcoming local IPOs
Tech
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX
Tech